Hims & Hers Health (HIMS)
(Delayed Data from NYSE)
$50.89 USD
-3.07 (-5.69%)
Updated Sep 16, 2025 03:59 PM ET
After-Market: $50.35 -0.54 (-1.06%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HIMS 50.89 -3.07(-5.69%)
Will HIMS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HIMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HIMS
Hims & Hers Expands AI and Technology Focus to Advance Digital Care
Company News for Sep 16, 2025
HIMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: Here's Why
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Other News for HIMS
Hims & Hers Stock (HIMS) Slumps as FDA Slams Its ‘False’ Weight Loss Drug Products
Trump announces $15B libel suit against New York Times: Morning Buzz
Trump announces $15B libel suit against New York Times: Morning Buzz
HIMS Stock Dips After FDA Warning on Marketing Claims
Trump announces $15 libel suit against New York Times: Morning Buzz